Innovative Engineered CAR-NK Cells Show Promise in Evasion of Immune Rejection and Enhanced Cancer Targeting
Researchers have developed engineered CAR-NK cells that can evade immune rejection and target cancer cells more effectively, promising safer and more accessible immunotherapy options.
Scientists from MIT and Harvard Medical School have developed a groundbreaking method to engineer CAR-NK (Chimeric Antigen Receptor-Natural Killer) cells that can better evade the immune system's defenses and more effectively target cancer cells. These immune cells, similar to the widely studied CAR-T cells, are reprogrammed to recognize and attack tumor cells, but a significant hurdle has been their rejection by the host immune response.
The new approach involves customizing CAR-NK cells to minimize their visibility to the patient’s immune system, specifically by reducing surface proteins called HLA class I proteins that normally trigger immune rejection. The researchers achieved this by engineering the cells to express short interfering RNA (siRNA) sequences to silence these proteins, while also introducing genes for proteins like PD-L1 or single-chain HLA-E (SCE) that bolster the NK cells’ ability to kill cancer cells.
In preclinical studies with mice possessing human-like immune systems, these modified CAR-NK cells demonstrated a remarkable ability to survive longer and nearly eradicate lymphoma tumors, outperforming unmodified or only CAR-expressing NK cells. Moreover, they showed a lower propensity to cause cytokine release syndrome, a dangerous side effect associated with immunotherapies.
This advancement paves the way for the development of off-the-shelf, ready-to-use CAR-NK therapies that can be administered immediately upon diagnosis, reducing the time and complexity associated with current personalized treatments. The team's work suggests that these CAR-NK cells could serve as a safer, more versatile alternative to CAR-T cells and may be adapted for treating various cancers, autoimmune diseases, and other conditions.
By enabling immune-evasive properties in NK cells, this research opens new horizons in cancer immunotherapy, promising more effective and accessible treatments in the near future.
Source: https://medicalxpress.com/news/2025-10-car-nk-cells-evade-immune.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Sudan Battles Its Most Severe Cholera Outbreak in Years with Over 40 Fatalities
Sudan faces its worst cholera outbreak in years, with over 40 fatalities amid ongoing conflict and displacement, highlighting urgent needs for aid and improved sanitation.
FDA Approves Injectable Leqembi for Early Alzheimer's Disease Treatment
The FDA has approved Leqembi Iqlik, a new subcutaneous injectable for early Alzheimer's disease, offering a faster, more convenient treatment option for patients after initial IV therapy.
Recall of 100,000 Amazon Mattresses Due to Fire Safety Concerns
Approximately 100,000 Crayan mattresses sold on Amazon are being recalled due to fire safety violations, with no injuries reported yet. Consumers are advised to stop using and contact the manufacturer for refunds.
Understanding How Myelin Damage in the Brain Can Trigger Seizures in Multiple Sclerosis
Recent research links demyelination in multiple sclerosis to increased seizure activity, highlighting potential targeted treatments to address this neurological complication.